A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays
is concurrent chemoradiation (CCRT) based on intensity-modulated radiation therapy (IMRT).
However, distant metastasis remains the major cause of treatment failure, especially in
patients with T1-4N2-3M0 diseases (N2-3 NPC). The investigators inferred that it was more
appropriate to consider N2-3 NPC as a systemic disease instead of a local disease. NACT of
sufficient intensity such as 4 cycles might be effective enough for control of the
pre-existing micrometastases. Therefore, the objective of this phase 3 multicenter randomized
controlled trial is to make a comparison between NACT of 4 cycles plus CCRT based on IMRT and
CCRT alone in N2-3 NPC on distant metastasis, survival and adverse reaction.